Sandbox GGC5
From Proteopedia
(29 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
- | ==''' | + | =='''Beta Lactamase'''== |
- | <StructureSection load=' | + | <StructureSection load='3ZWF' size='340' side='right' caption='tRNAse Z Metallo-Beta Lactamase (homosapien)' scene=''> |
- | + | ||
- | + | ||
- | + | Beta Lactamase is a highly conserved enzyme in both prokaryotes and eukaryotes. In prokaryotes, it gives bacteria such as ''E.coli'' antibiotic resistance. In eukaryotes, it acts as exo and endonucleases to regulate transcription activity. | |
- | + | ||
- | + | =='''Background Information'''== | |
- | + | There are several classes of antibiotics, including cephalosporin and penicillin <ref>doi: 10.1016/j.jmb.2019.04.002</ref>. Some common examples of specific drugs in these classes include cefazolin, cefadroxil, penicillin, ampicillin, and methicillin <ref>doi: 10.1016/j.jmb.2019.04.002</ref>. These antibiotics function by preventing bacteria from forming their cell wall, regardless if the bacteria are gram positive or gram negative <ref>doi: 10.1016/j.jmb.2019.04.002</ref>. These antibiotics all contain a beta-lactam ring <ref>https://doi.org/10.1021/cr030102i</ref>. | |
- | The | + | Inside of the gram positive or gram negative bacteria, there is a protein called the penicillin binding protein. The penicillin binding proteins (PBPs) are what help the peptidoglycan walls to form by linking NAG and NAM chains together. The beta-lactam ring fits particularly well into the PBP, which is how antibiotics like penicillin prevent bacteria from synthesizing its cell wall. |
- | + | [[Image:beta lactam ring in antibiotics.png]] | |
+ | Beta Lactam Ring present in Antibiotics | ||
- | + | [[Image:Penicillin inhibition.svg]] | |
+ | Penicillin inhibition | ||
- | == ''' | + | =='''Mechanism of Antibiotic Beta Lactam Ring Resistance'''== |
- | ''' | + | Bacteria such as ''E. coli'' make and excrete an enzyme called beta lactamase <ref>DOI: 10.1080/10409230701279118</ref>. Bacteria can become resistant to antibiotics that contain lactam rings when the B-lactamase enzyme attacks the beta lactam ring (classified as a hydrolase). Once the beta lactam ring is sliced open, it is no longer functional <ref> DOI 10.2210/pdb3ZWF/pdb </ref>. |
+ | |||
+ | =='''Beta Lactamase in Humans (PDB: 3ZWF)'''== | ||
- | + | In order to make mature tRNAs, first they have to be processed <ref>https://doi.org/10.1101/575373</ref>. The enzyme that does tRNA processing is called TRNase Z. In humans, the form of beta lactamase formed uses a zinc-dependent mechanism, noted as metallo-beta lactamase <ref>DOI: 10.1080/10409230701279118</ref>. These enzymes in humans function to regulate nuclear activity, providing exo and endonuclease activity. | |
- | ''' | + | =='''Structural highlights'''== |
- | + | Macromolecules: | |
+ | Two chains (A,B) of Zinc phosphodiesterase ELAC Protein 1 <ref>DOI 10.2210/pdb3ZWF/pdb</ref>. | ||
- | '' | + | ''Unique Ligands'' |
- | This disorder is characterized by ventricular dilation and impaired systolic function. This disorder results in congestive heart failure and arrhythmia, ultimately leading to a high possibility of premature death. This disease is often indicated by natural variants in the following locations: 54, 743, 976, 3799, 4465 or 32996. All of these variants affect the interaction with the TCAP/telethonin. <ref>PMID:11846417</ref> | ||
- | + | - Phosphate (PO4) ligand on chains A and B of Zinc phosphodiesterase ELAC Protein 1 <ref>DOI 10.2210/pdb3ZWF/pdb</ref>. | |
- | + | <scene name='78/781193/Po4/1'>PO4 Ligand</scene> | |
- | + | - Zinc (Zn) ligand on chains A and B of Zinc phosphodiesterase ELAC Protein 1 <ref>DOI 10.2210/pdb3ZWF/pdb</ref>. | |
- | This disease is characterized by progressive weakness of the pelvic and shoulder girdle muscles. Muscular dystrophy is an autosomal recessive denerative myopathy that results in severe disability observed within 20 years of its onset. <ref>PMID:12145747</ref> | ||
- | '' | + | <scene name='78/781193/2_zincs/1'>Zinc ions are adjacent to the phosphate to balance the charge</scene> |
- | + | - 2007 hydrophobic amino acid residues <ref>DOI 10.2210/pdb3ZWF/pdb</ref>. | |
+ | <scene name='78/781193/Hydrophobic_amino_acids/1'>hydrophobic amino acid properties </scene> | ||
- | + | - 1878 polar amino acid residues <ref>DOI 10.2210/pdb3ZWF/pdb</ref>. | |
+ | <scene name='78/781193/Polar_amino_acids/1'>polar amino acids</scene> | ||
- | + | - Sodium (Na+) ion on chain B of Zinc phosphodiesterase ELAC Protein 1 <ref>DOI 10.2210/pdb3ZWF/pdb</ref>. | |
+ | <scene name='78/781193/Sodium_ion_enlarged/1'>Sodium Ion present</scene> | ||
- | •This is the <scene name='78/781193/Titin_rainbow_tc/1'>rainbow</scene> version of the titin molecule. This structure is colored to differentiate each chain, starting with the blue 5' amino end, ending with the red 3' carboxyl end. | ||
- | + | </StructureSection> | |
- | + | =='''Disease'''== | |
+ | If there are mutations in the tRNase Z metallo-beta lactamases, these enzymes have been implicated in several diseases including prostate cancer <ref>DOI: 10.1080/10409230701279118</ref>. While there is still much to learn about how these lactamases work inter-connectedly with other enzymes, research suggests that metallo-beta lactamases function as cleavage and polyadenylation factors <ref>https://doi.org/10.1101/575373</ref>. | ||
- | •This structure view highlights the <scene name='78/781193/Titin_mutation_tc_val/2'>VAL residue 54</scene>.The VAL residue located at #54 is one of the mutations present in the cardiomyopathy,familial hypertrophic 9, disease. This VAL residue is replaced by a MET residue when the disease is present in an infected individual. <ref>PMID:10462489</ref> | ||
- | + | == '''Evolutionary Considerations''' == | |
+ | |||
+ | Beta Lactamase protein structure is highly conserved across both prokaryotes and eukaryotes <ref>doi: https://doi.org/10.1101/819797</ref>. Their presence indicates that these proteins are highly adaptable, with a wide range of substrates <ref>https://doi.org/10.1101/575373</ref>. The highly conserved nature of this structure suggests that the genetic material for beta lactamase is ancient in origin <ref>https://doi.org/10.1101/575373</ref>. They have found early beta lactamases in deep sea sediment, before the first antibiotic was ever encountered. | ||
- | •These are the <scene name='78/781193/Titin_pro_tc/1'>Proline residues</scene> located in the PEVK domain that is vital to the elasticity characteristics of titin. | ||
- | </StructureSection> | ||
== '''References''' == | == '''References''' == | ||
<references/> | <references/> | ||
+ | |||
+ | [1] | ||
+ | [2] | ||
+ | [3] | ||
+ | [4] | ||
+ | [5] | ||
+ | [6] | ||
+ | [7] | ||
+ | [8] |
Current revision
Contents |
Beta Lactamase
|
Disease
If there are mutations in the tRNase Z metallo-beta lactamases, these enzymes have been implicated in several diseases including prostate cancer [15]. While there is still much to learn about how these lactamases work inter-connectedly with other enzymes, research suggests that metallo-beta lactamases function as cleavage and polyadenylation factors [16].
Evolutionary Considerations
Beta Lactamase protein structure is highly conserved across both prokaryotes and eukaryotes [17]. Their presence indicates that these proteins are highly adaptable, with a wide range of substrates [18]. The highly conserved nature of this structure suggests that the genetic material for beta lactamase is ancient in origin [19]. They have found early beta lactamases in deep sea sediment, before the first antibiotic was ever encountered.
References
- ↑ Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi Y, Spencer J. beta-Lactamases and beta-Lactamase Inhibitors in the 21st Century. J Mol Biol. 2019 Aug 23;431(18):3472-3500. doi: 10.1016/j.jmb.2019.04.002. Epub, 2019 Apr 5. PMID:30959050 doi:http://dx.doi.org/10.1016/j.jmb.2019.04.002
- ↑ Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi Y, Spencer J. beta-Lactamases and beta-Lactamase Inhibitors in the 21st Century. J Mol Biol. 2019 Aug 23;431(18):3472-3500. doi: 10.1016/j.jmb.2019.04.002. Epub, 2019 Apr 5. PMID:30959050 doi:http://dx.doi.org/10.1016/j.jmb.2019.04.002
- ↑ Tooke CL, Hinchliffe P, Bragginton EC, Colenso CK, Hirvonen VHA, Takebayashi Y, Spencer J. beta-Lactamases and beta-Lactamase Inhibitors in the 21st Century. J Mol Biol. 2019 Aug 23;431(18):3472-3500. doi: 10.1016/j.jmb.2019.04.002. Epub, 2019 Apr 5. PMID:30959050 doi:http://dx.doi.org/10.1016/j.jmb.2019.04.002
- ↑ https://doi.org/10.1021/cr030102i
- ↑ Dominski Z. Nucleases of the metallo-beta-lactamase family and their role in DNA and RNA metabolism. Crit Rev Biochem Mol Biol. 2007 Mar-Apr;42(2):67-93. doi:, 10.1080/10409230701279118. PMID:17453916 doi:http://dx.doi.org/10.1080/10409230701279118
- ↑ doi: https://dx.doi.org/10.2210/pdb3ZWF/pdb
- ↑ https://doi.org/10.1101/575373
- ↑ Dominski Z. Nucleases of the metallo-beta-lactamase family and their role in DNA and RNA metabolism. Crit Rev Biochem Mol Biol. 2007 Mar-Apr;42(2):67-93. doi:, 10.1080/10409230701279118. PMID:17453916 doi:http://dx.doi.org/10.1080/10409230701279118
- ↑ doi: https://dx.doi.org/10.2210/pdb3ZWF/pdb
- ↑ doi: https://dx.doi.org/10.2210/pdb3ZWF/pdb
- ↑ doi: https://dx.doi.org/10.2210/pdb3ZWF/pdb
- ↑ doi: https://dx.doi.org/10.2210/pdb3ZWF/pdb
- ↑ doi: https://dx.doi.org/10.2210/pdb3ZWF/pdb
- ↑ doi: https://dx.doi.org/10.2210/pdb3ZWF/pdb
- ↑ Dominski Z. Nucleases of the metallo-beta-lactamase family and their role in DNA and RNA metabolism. Crit Rev Biochem Mol Biol. 2007 Mar-Apr;42(2):67-93. doi:, 10.1080/10409230701279118. PMID:17453916 doi:http://dx.doi.org/10.1080/10409230701279118
- ↑ https://doi.org/10.1101/575373
- ↑ doi: https://dx.doi.org/https
- ↑ https://doi.org/10.1101/575373
- ↑ https://doi.org/10.1101/575373
[1] [2] [3] [4] [5] [6] [7] [8]